Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2002 Oct;78(924):590–595. doi: 10.1136/pmj.78.924.590

Prostate cancer

D Mazhar 1, J Waxman 1
PMCID: PMC1742511  PMID: 12415080

Abstract

It is a paradigm in cancer treatment that early detection and treatment improves survival. However, although screening measures lead to a higher rate of detection, for small bulk localised prostate cancer it remains unclear whether early detection and early treatment will lead to an overall decrease in mortality. The management options include surveillance, radiotherapy, and radical prostatectomy but there is no evidence base to evaluate the benefits of each approach. Advanced prostate cancer is managed by hormonal therapy. There have been major changes in treatment over the last two decades with the use of more humane treatment and developments in both chemotherapy and radiation. In this article we review the natural history and management of prostate cancer.

Full Text

The Full Text of this article is available as a PDF (106.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BUELL P., DUNN J. E., Jr CANCER MORTALITY AMONG JAPANESE ISSEI AND NISEI OF CALIFORNIA. Cancer. 1965 May;18:656–664. doi: 10.1002/1097-0142(196505)18:5<656::aid-cncr2820180515>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  2. Beral V., Inskip H., Fraser P., Booth M., Coleman D., Rose G. Mortality of employees of the United Kingdom Atomic Energy Authority, 1946-1979. Br Med J (Clin Res Ed) 1985 Aug 17;291(6493):440–447. doi: 10.1136/bmj.291.6493.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bishop M. C. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol. 1996 Dec;78(6):921–928. doi: 10.1046/j.1464-410x.1996.23320.x. [DOI] [PubMed] [Google Scholar]
  4. Blasko J. C., Wallner K., Grimm P. D., Ragde H. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 1995 Sep;154(3):1096–1099. [PubMed] [Google Scholar]
  5. Bolla M., Gonzalez D., Warde P., Dubois J. B., Mirimanoff R. O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295–300. doi: 10.1056/NEJM199707313370502. [DOI] [PubMed] [Google Scholar]
  6. Bostwick D. G., Grignon D. J., Hammond M. E., Amin M. B., Cohen M., Crawford D., Gospadarowicz M., Kaplan R. S., Miller D. S., Montironi R. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul;124(7):995–1000. doi: 10.5858/2000-124-0995-PFIPC. [DOI] [PubMed] [Google Scholar]
  7. Brawer M. K. Prostate-specific antigen: current status. CA Cancer J Clin. 1999 Sep-Oct;49(5):264–281. doi: 10.3322/canjclin.49.5.264. [DOI] [PubMed] [Google Scholar]
  8. Brawley O. W., Parnes H. Prostate cancer prevention trials in the USA. Eur J Cancer. 2000 Jun;36(10):1312–1315. doi: 10.1016/s0959-8049(00)00105-2. [DOI] [PubMed] [Google Scholar]
  9. Brawley O. W. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer. 1997 Nov 1;80(9):1857–1863. doi: 10.1002/(sici)1097-0142(19971101)80:9<1857::aid-cncr26>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  10. Burton J. L., Oakley N., Anderson J. B. Recent advances in the histopathology and molecular biology of prostate cancer. BJU Int. 2000 Jan;85(1):87–94. doi: 10.1046/j.1464-410x.2000.00422.x. [DOI] [PubMed] [Google Scholar]
  11. Chodak G. W., Thisted R. A., Gerber G. S., Johansson J. E., Adolfsson J., Jones G. W., Chisholm G. D., Moskovitz B., Livne P. M., Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994 Jan 27;330(4):242–248. doi: 10.1056/NEJM199401273300403. [DOI] [PubMed] [Google Scholar]
  12. Coley C. M., Barry M. J., Fleming C., Mulley A. G. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med. 1997 Mar 1;126(5):394–406. doi: 10.7326/0003-4819-126-5-199703010-00010. [DOI] [PubMed] [Google Scholar]
  13. Crook J., Esche B., Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology. 1996 Mar;47(3):387–394. doi: 10.1016/S0090-4295(99)80458-0. [DOI] [PubMed] [Google Scholar]
  14. Duncan W., Warde P., Catton C. N., Munro A. J., Lakier R., Gadalla T., Gospodarowicz M. K. Carcinoma of the prostate: results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):203–210. doi: 10.1016/0360-3016(93)90198-5. [DOI] [PubMed] [Google Scholar]
  15. Feneley M. R., Gillatt D. A., Hehir M., Kirby R. S. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome. Br J Urol. 1996 Dec;78(6):911–920. doi: 10.1046/j.1464-410x.1996.00619.x. [DOI] [PubMed] [Google Scholar]
  16. Fleshner N. E., Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol. 1995 Nov;154(5):1642–1646. [PubMed] [Google Scholar]
  17. Garnick M. B. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology. 1986 Jan;27(1 Suppl):21–28. [PubMed] [Google Scholar]
  18. Goktas S., Crawford E. D. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999 Apr;26(2):162–173. [PubMed] [Google Scholar]
  19. Hayes R. B., Liff J. M., Pottern L. M., Greenberg R. S., Schoenberg J. B., Schwartz A. G., Swanson G. M., Silverman D. T., Brown L. M., Hoover R. N. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer. 1995 Jan 27;60(3):361–364. doi: 10.1002/ijc.2910600315. [DOI] [PubMed] [Google Scholar]
  20. Lee H. H., Warde P., Jewett M. A. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int. 1999 Mar;83(4):438–448. doi: 10.1046/j.1464-410x.1999.00953.x. [DOI] [PubMed] [Google Scholar]
  21. Oh W. K., Kantoff P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998 Oct;160(4):1220–1229. [PubMed] [Google Scholar]
  22. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J Clin. 1997 Jan-Feb;47(1):5–27. doi: 10.3322/canjclin.47.1.5. [DOI] [PubMed] [Google Scholar]
  23. Parmar H., Edwards L., Phillips R. H., Allen L., Lightman S. L. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol. 1987 Mar;59(3):248–254. doi: 10.1111/j.1464-410x.1987.tb04616.x. [DOI] [PubMed] [Google Scholar]
  24. Pilepich M. V., Krall J. M., al-Sarraf M., John M. J., Doggett R. L., Sause W. T., Lawton C. A., Abrams R. A., Rotman M., Rubin P. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995 Apr;45(4):616–623. doi: 10.1016/s0090-4295(99)80053-3. [DOI] [PubMed] [Google Scholar]
  25. Pisters L. L. The challenge of locally advanced prostate cancer. Semin Oncol. 1999 Apr;26(2):202–216. [PubMed] [Google Scholar]
  26. Plowman P. N. Glucocorticoids and prostate cancer in castrate men. J Clin Oncol. 1999 Dec;17(12):3856–3860. [PubMed] [Google Scholar]
  27. Pollack A., Zagars G. K., Rosen I. I. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol. 1999 Apr;26(2):150–161. [PubMed] [Google Scholar]
  28. Prior T., Waxman J. Localised prostate cancer: can we do better? There have been some advances in local control, but little impact on survival. BMJ. 2000 Jan 8;320(7227):69–70. doi: 10.1136/bmj.320.7227.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Qian J., Wollan P., Bostwick D. G. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol. 1997 Feb;28(2):143–148. doi: 10.1016/s0046-8177(97)90097-6. [DOI] [PubMed] [Google Scholar]
  30. Ragde H., Blasko J. C., Grimm P. D., Kenny G. M., Sylvester J. E., Hoak D. C., Landin K., Cavanagh W. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 1997 Aug 1;80(3):442–453. doi: 10.1002/(sici)1097-0142(19970801)80:3<442::aid-cncr12>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  31. Richie J. P., Catalona W. J., Ahmann F. R., Hudson M. A., Scardino P. T., Flanigan R. C., deKernion J. B., Ratliff T. L., Kavoussi L. R., Dalkin B. L. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993 Oct;42(4):365–374. doi: 10.1016/0090-4295(93)90359-i. [DOI] [PubMed] [Google Scholar]
  32. Ruckle H. C., Klee G. G., Oesterling J. E. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc. 1994 Jan;69(1):69–79. doi: 10.1016/s0025-6196(12)61615-2. [DOI] [PubMed] [Google Scholar]
  33. Schiebler M. L., Schnall M. D., Pollack H. M., Lenkinski R. E., Tomaszewski J. E., Wein A. J., Whittington R., Rauschning W., Kressel H. Y. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology. 1993 Nov;189(2):339–352. doi: 10.1148/radiology.189.2.8210358. [DOI] [PubMed] [Google Scholar]
  34. Schröder F. H. Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU Int. 1999 Jan;83(2):161–170. doi: 10.1046/j.1464-410x.1999.00955.x. [DOI] [PubMed] [Google Scholar]
  35. Silverberg E., Lubera J. A. A review of American Cancer Society estimates of cancer cases and deaths. CA Cancer J Clin. 1983 Jan-Feb;33(1):2–8. doi: 10.3322/canjclin.33.1.2. [DOI] [PubMed] [Google Scholar]
  36. Smith J. A., Jr, Scardino P. T., Resnick M. I., Hernandez A. D., Rose S. C., Egger M. J. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol. 1997 Mar;157(3):902–906. [PubMed] [Google Scholar]
  37. Stilmant M. M., Kuligowska E. Transrectal ultrasound screening for prostatic adenocarcinoma with histopathological correlation. Factors affecting specificity. Cancer. 1993 Mar 15;71(6):2041–2047. doi: 10.1002/1097-0142(19930315)71:6<2041::aid-cncr2820710619>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  38. Sullivan L. D., Weir M. J., Kinahan J. F., Taylor D. L. A comparison of the relative merits of radical perineal and radical retropubic prostatectomy. BJU Int. 2000 Jan;85(1):95–100. doi: 10.1046/j.1464-410x.2000.00405.x. [DOI] [PubMed] [Google Scholar]
  39. Tannock I. F., Osoba D., Stockler M. R., Ernst D. S., Neville A. J., Moore M. J., Armitage G. R., Wilson J. J., Venner P. M., Coppin C. M. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756–1764. doi: 10.1200/JCO.1996.14.6.1756. [DOI] [PubMed] [Google Scholar]
  40. Teng D. H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K. L., Vinson V. L., Gumpper K. L. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997 Dec 1;57(23):5221–5225. [PubMed] [Google Scholar]
  41. Wang J, Waxman J. Chemotherapy for prostate cancer. Urol Oncol. 2000 Apr 1;5(3):93–96. doi: 10.1016/s1078-1439(99)00054-x. [DOI] [PubMed] [Google Scholar]
  42. Waxman J., Man A., Hendry W. F., Whitfield H. N., Besser G. M., Tiptaft R. C., Paris A. M., Oliver R. T. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) 1985 Nov 16;291(6506):1387–1388. doi: 10.1136/bmj.291.6506.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES